Trials / Completed
CompletedNCT00795574
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Florida Academic Dermatology Centers · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Accepted
Summary
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | infliximab | Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase. |
| DRUG | Placebo Comparator | 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period. |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-11-21
- Last updated
- 2008-11-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00795574. Inclusion in this directory is not an endorsement.